Stephen Cunningham, MD
Stephen Cunningham, MD, is a 25-year pharmaceutical veteran who has led teams that have developed, obtained regulatory approvals for, and launched numerous significant pharmaceuticals. He has global experience leading cross-functional teams from Phase 1 through life cycle management in the areas of Neuroscience, Cardiovascular, Metabolism, Respiratory, Immunology, Oncology, Women’s Health, Transplant and Clinical Pharmacology. During his career, Dr. Cunningham led and developed diverse cross-functional teams in Europe, Japan, Asia, Canada and the United States, and has broad experience in setting strategic direction, delivering projects, restructuring organizations and implementing transformational organizational change. Dr. Cunningham began his career at ICI Pharmaceuticals, holding global positions of increasing responsibility at ICI, Zeneca and lastly Novartis. After joining Novartis as Head of Medical Affairs in the US, Dr. Cunningham quickly assumed the role of Chief Scientific Officer and Head of US Clinical Development, Medical Affairs and Evidence-Based Medicine. While at Novartis he built a world class Novartis US Clinical Development and Medical Affairs organization supporting drug development, launch and life cycle management of products worldwide. Dr. Cunningham earned his MB, BCh, BAO and MD in Cardiology from Queen's University in Belfast.